Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001087294-13-000017
Filing Date
2013-11-06
Accepted
2013-11-06 17:09:58
Documents
10
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q q3201310q.htm 10-Q 520289
2 EX 31.1 q32013-exhibit311.htm EX-31.1 15940
3 EX 31.2 q32013-exhibit312.htm EX-31.2 15950
4 EX 32.1 q32013-exhibit321.htm EX-32.1 8108
  Complete submission text file 0001087294-13-000017.txt   3220749

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cpix-20130930.xml EX-101.INS 377939
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20130930.xsd EX-101.SCH 26700
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20130930_cal.xml EX-101.CAL 45490
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20130930_def.xml EX-101.DEF 131425
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20130930_lab.xml EX-101.LAB 315804
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20130930_pre.xml EX-101.PRE 172214
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 10-Q | Act: 34 | File No.: 001-33637 | Film No.: 131197354
SIC: 2834 Pharmaceutical Preparations